An international research team led by the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) and IBM Research developed a synthetic molecule that can kill five deadly types of multidrug-resistant bacteria with limited, if any, side effects. Their new material could be developed into an antimicrobial drug to treat patients with antibioticresistant infections.
This finding was reported in the scientific journal Nature Communications.
Superbugs that are resistant to antibiotics are a serious health threat. According to the UK Review on Antimicrobial Resistance, superbugs kill around 700,000 people worldwide each year. By 2050, 10 million people could die each year if existing antibiotics continue to lose their effectiveness.
“There is an urgent global need for new antimicrobials that are effective against superbugs. The situation has become more acute because bacteria are starting to develop resistance to the last-line antibiotics, which are given only to patients infected with bacteria resistant to available antibiotics,” said Professor Jackie Y. Ying, Executive Director of IBN.
The research community is trying to develop alternatives to antibiotics using synthetic polymers. However, the antimicrobial polymers developed so far are either too toxic for clinical use, not biodegradable or can only target one type of bacteria.
To address this problem, Dr Yi Yan Yang from IBN brought together a multidisciplinary research team from the US, China and Singapore to develop a new class of antimicrobial polymers called guanidinium-functionalized polycarbonates with a unique killing mechanism that can target a broad range of multidrug-resistant bacteria. It is biodegradable and non-toxic to human cells.
The polymer kills bacteria in the following way. First, the polymer binds specifically to the bacterial cell. Then, the polymer is transported across the bacterial cell membrane into the cytoplasm, where it causes precipitation of the cell contents (proteins and genes), resulting in cell death.
The team tested the polymers on mice infected with five hard-to-treat multidrug-resistant bacteria: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, methicillinresistant Staphylococcus aureu and Pseudomonas aeruginosa. These superbugs are commonly acquired by patients in the hospitals and can cause systemic infections that lead to septic shock and multiple organ failure. The results showed that the bacteria were effectively removed from the mice and no toxicity was observed.
The researchers then further tested the effectiveness of the polymers on mice with two types of systemic infections caused by superbugs: peritonitis (an infection of the stomach’s inner lining) and lung infections from Pseudomonas aeruginosa. The polymers eliminated the bacterial infections in both groups of mice with negligible toxicity.
Dr Yi Yan Yang, Group Leader at IBN said, “We have demonstrated the first example of a biodegradable synthetic macromolecule with broad-spectrum antimicrobial activity in mice, unique killing mechanism and no toxicity. Once the polymer finishes its job of killing the bacteria, it will be naturally degraded after three days and will not remain in the body. This antimicrobial agent shows great promise for the treatment and prevention of multidrug-resistant systemic infections.”
“This study illustrates the potential for this new research field we denote as ‘macromolecular therapeutics’ to create entirely new classes of treatments for multiple diseases,” said Dr James Hedrick, Distinguished Research Staff Member, IBM Research – Almaden, San Jose, California. “In 2016, we demonstrated the efficacy of synthetic polymers to combat deadly viral diseases. The current research for treating bacterial infections rounds out our ability to someday treat a spectrum of infectious diseases with a single, new type of mechanism without the onset of resistance.”
To determine whether the bacteria will develop any resistance to the polymer, the team collaborated with Dr Paola Florez de Sessions at A*STAR’s Genome Institute of Singapore and the Cell Engineering group of Dr Simone Bianco at IBM Research – Almaden to perform genomic analysis. They found that the bacteria did not show any resistance development even after multiple treatments with the polymer.
The Latest on: Antimicrobial drug
Boston-area companies bet on antibiotic development, even as big drug makers step back
on July 19, 2018 at 1:42 am
Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research Subscriber-only networking even... […]
Rise in non-prescription antibiotic use highlights urgent need for better enforcement: study
on July 18, 2018 at 10:34 pm
Economic growth and better access contributed to the global increase in supply of the antimicrobial drugs, with the majority of the overall rise in consumption occurring in places including Brazil, In... […]
Countries accused of failing to meet pledge to tackle antibiotic misuse
on July 18, 2018 at 9:40 pm
head of the WHO’s antimicrobial resistance monitoring and national action plan support team, told the Thomson Reuters Foundation. She said antibiotics were used to fight child mortality, malaria, tube... […]
Bacterial ‘armour’ could provide a target for new antibiotic drugs
on July 18, 2018 at 10:52 am
Targeting the “suit of armour” that surrounds many types of bacteria could usher in a new generation of antibiotics, say scientists. Until now the thin membrane that wraps like cling film around the b... […]
Drug price measure barred from ballot & unnecessary antibiotic use
on July 17, 2018 at 11:44 pm
New on the streets: Gabapentin, a drug for nerve pain, and a new target of misuse Why fentanyl is deadlier than heroin, in a single… Why fentanyl is deadlier than heroin, in a single photo Recommended ... […]
French Biotech Raises €12.5M for Antibiotic Booster Drugs
on July 13, 2018 at 6:31 am
French-biotech Antabio closed €12.5M at series A to fund its pipeline of antibiotic booster drugs that should help in the global fight against antimicrobial resistance. After raising €7.3M last year, ... […]
Do Probiotics Mitigate or Contribute to Antibiotic Resistance?
on July 12, 2018 at 5:00 am
“The results will help develop intervention strategies to mitigate AMR, as well as maintain the usefulness of antimicrobial drugs in swine production,” researchers point out. Click here for more detai... […]
Reducing use of antimicrobial drugs in livestock in low-income countries: Two scientists reflect on options
on July 11, 2018 at 10:13 pm
Graphic by Peter Hermes Furian / Shutterstock. Delia Grace Randolph, a veterinary epidemiologist and food safety expert who co-leads the Animal and Human Health program at the International Livestock ... […]
Can nanoparticles be used to lower antibiotic resistance?
on July 10, 2018 at 12:02 pm
Antibiotic resistance is one of the world's most serious threats ... allowing the researchers to test how the drugs affect the microbiome at different dosages. The goal is to determine if administerin... […]
Thermal Protein Profiling May Offer New Insights on Antibiotic Resistance
on July 9, 2018 at 5:10 am
“Finally, we combined in vitro and in vivo TPP to identify targets of known antimicrobial drugs and to map their downstream effects. In conclusion, we demonstrate that TPP can be used in bacteria to p... […]
via Google News and Bing News